aod9604 human clinical trials efficacy weight loss side effects What are the benefits and risks of using AOD-9604 (Anti-Obesity Drug) for loss? The Journey of AOD-9604: From

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

We pair it with GHK-Cu, which handles tissue repair and collagen production

Clinical trials confirmed no IGF-1 elevation and no negative impact on glucose metabolism, even during 24-week treatment periods

By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals

1) include 12 genetically distinct metabolic disorders, inherited as an autosomal recessive trait, with an estimated cumulative incidence from 1:6,500 to 1:110,000 [1]